Preliminary clinical data on a new photodynamic therapy photosensitizer, 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) for treatment of obstructive esophageal cancer

Thomas J. Dougherty; Ravindra K. Pandey; Hector R. Nava; Judy A. Smith; Harold O. Douglass; Stephen B. Edge; David A. Bellnier; Linda O'Malley; Michele Cooper

Preliminary clinical data on a new photodynamic therapy photosensitizer, 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) for treatment of obstructive esophageal cancer

Thomas J. Dougherty
, Ravindra K. Pandey
, Hector R. Nava
, Judy A. Smith
, Harold O. Douglass
, Stephen B. Edge
, David A. Bellnier
, Linda O'Malley
, Michele Cooper

Institute for Lasers Photonics and Biophotonics

Roswell Park Cancer Institute

Research output: Contribution to journal › Conference article › peer-review

32 Scopus citations

Abstract

The hexyl ether derivative of pyropheophorbide-a, 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH), has been identified as an optimally active in vivo photosensitizer in pre-clinical studies and has been evaluated clinically in obstructive esophageal cancer in five patients to date. The photosensitizer appears to have no systemic toxicity and be effective at low drug and light doses. Further, cutaneous photosensitivity appears to persist only 5-7 days.

Original language	English
Pages (from-to)	25-27
Number of pages	3
Journal	Proceedings of SPIE - The International Society for Optical Engineering
Volume	3909
State	Published - 2000
Event	Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy IX - San Jose, CA, USA Duration: Jan 22 2000 → Jan 23 2000

Cite this

Dougherty, T. J., Pandey, R. K., Nava, H. R., Smith, J. A., Douglass, H. O., Edge, S. B., Bellnier, D. A., O'Malley, L., & Cooper, M. (2000). Preliminary clinical data on a new photodynamic therapy photosensitizer, 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) for treatment of obstructive esophageal cancer. Proceedings of SPIE - The International Society for Optical Engineering, 3909, 25-27.

@article{d0ba6429893f43a5a661e73839123883,

title = "Preliminary clinical data on a new photodynamic therapy photosensitizer, 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) for treatment of obstructive esophageal cancer",

abstract = "The hexyl ether derivative of pyropheophorbide-a, 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH), has been identified as an optimally active in vivo photosensitizer in pre-clinical studies and has been evaluated clinically in obstructive esophageal cancer in five patients to date. The photosensitizer appears to have no systemic toxicity and be effective at low drug and light doses. Further, cutaneous photosensitivity appears to persist only 5-7 days.",

author = "Dougherty, \{Thomas J.\} and Pandey, \{Ravindra K.\} and Nava, \{Hector R.\} and Smith, \{Judy A.\} and Douglass, \{Harold O.\} and Edge, \{Stephen B.\} and Bellnier, \{David A.\} and Linda O'Malley and Michele Cooper",

year = "2000",

language = "English",

volume = "3909",

pages = "25--27",

journal = "Proceedings of SPIE - The International Society for Optical Engineering",

issn = "0277-786X",

publisher = "SPIE",

note = "Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy IX ; Conference date: 22-01-2000 Through 23-01-2000",

}

Dougherty, TJ, Pandey, RK, Nava, HR, Smith, JA, Douglass, HO, Edge, SB, Bellnier, DA, O'Malley, L & Cooper, M 2000, 'Preliminary clinical data on a new photodynamic therapy photosensitizer, 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) for treatment of obstructive esophageal cancer', Proceedings of SPIE - The International Society for Optical Engineering, vol. 3909, pp. 25-27.

Preliminary clinical data on a new photodynamic therapy photosensitizer, 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) for treatment of obstructive esophageal cancer. / Dougherty, Thomas J.; Pandey, Ravindra K.; Nava, Hector R. et al.
In: Proceedings of SPIE - The International Society for Optical Engineering, Vol. 3909, 2000, p. 25-27.

Research output: Contribution to journal › Conference article › peer-review

TY - JOUR

T1 - Preliminary clinical data on a new photodynamic therapy photosensitizer, 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) for treatment of obstructive esophageal cancer

AU - Dougherty, Thomas J.

AU - Pandey, Ravindra K.

AU - Nava, Hector R.

AU - Smith, Judy A.

AU - Douglass, Harold O.

AU - Edge, Stephen B.

AU - Bellnier, David A.

AU - O'Malley, Linda

AU - Cooper, Michele

PY - 2000

Y1 - 2000

N2 - The hexyl ether derivative of pyropheophorbide-a, 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH), has been identified as an optimally active in vivo photosensitizer in pre-clinical studies and has been evaluated clinically in obstructive esophageal cancer in five patients to date. The photosensitizer appears to have no systemic toxicity and be effective at low drug and light doses. Further, cutaneous photosensitivity appears to persist only 5-7 days.

AB - The hexyl ether derivative of pyropheophorbide-a, 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH), has been identified as an optimally active in vivo photosensitizer in pre-clinical studies and has been evaluated clinically in obstructive esophageal cancer in five patients to date. The photosensitizer appears to have no systemic toxicity and be effective at low drug and light doses. Further, cutaneous photosensitivity appears to persist only 5-7 days.

UR - https://www.scopus.com/pages/publications/0033903913

M3 - Conference article

AN - SCOPUS:0033903913

SN - 0277-786X

VL - 3909

SP - 25

EP - 27

JO - Proceedings of SPIE - The International Society for Optical Engineering

JF - Proceedings of SPIE - The International Society for Optical Engineering

T2 - Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy IX

Y2 - 22 January 2000 through 23 January 2000

ER -

Preliminary clinical data on a new photodynamic therapy photosensitizer, 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) for treatment of obstructive esophageal cancer

Abstract

Other files and links

Fingerprint

Cite this